舒肝解郁胶囊联合齐拉西酮治疗精神分裂症临床研究

Clinical Study on Shugan Jieyu Capsules Combined with Ziprasidone for Schizophrenia

目的:观察舒肝解郁胶囊联合齐拉西酮治疗精神分裂症的临床疗效,以及对患者认知功能及血管内皮生长因子(VEGF)、胶质细胞源性神经营养因子(GDNF)、表皮生长因子(EGF)水平的影响。方法:选取80例精神分裂症患者,按照随机数字表法分为对照组和观察组,每组40例。对照组给予齐拉西酮治疗,观察组在对照组基础上加服舒肝解郁胶囊治疗,2组均治疗8周。比较2组临床疗效、不良反应发生率;比较2组治疗前后认知功能及VEGF、GDNF、EGF水平。结果:观察组总有效率95.00%,高于对照组77.50%(P<0.05)。治疗后,2组阴性症状、阳性症状、一般精神病理症状评分及总分均较治疗前降低(P<0.05),观察组阴性症状、阳性症状、一般精神病理症状评分及总分均低于对照组(P<0.05)。治疗后,2组认知功能成套测验系统(MCCB)各维度评分均较治疗前升高(P<0.05),观察组MCCB各维度评分均高于对照组(P<0.05)。治疗后,2组VEGF、GDNF水平均较治疗前升高(P<0.05),EGF水平均较治疗前降低(P<0.05);观察组VEGF、GDNF水平均高于对照组(P<0.05),EGF水平低于对照组(P<0.05)。观察组不良反应发生率15.00%,与对照组12.50%比较,差异无统计学意义(P>0.05)。结论:舒肝解郁胶囊联合齐拉西酮治疗精神分裂症可提高临床疗效,改善患者的认知功能,调节VEGF、GDNF、EGF水平,安全性较好。

Objective:To observe the clinical effect of Shugan Jieyu capsules combined with ziprasidone for schizophrenia,and its effect on cognitive function and levels of vascular endothelial growth factor(VEGF),glial-cell line derived neurotrophic factor(GDNF)and epidermal growth factor(EGF).Methods:A total of 80 cases of patients with schizophrenia were selected and divided into the control group and the observation group according to the random number table method,with 40 cases in each group.The control group was treated with ziprasidone,and the observation group was additionally treated with Shugan Jieyu capsules based on the treatment of the control group.Both groups were treated for eight weeks.The clinical effects and incidence of adverse reactions in the two groups were compared.Before and after treatment,the cognitive function and levels of VEGF,GDNF and EGF in the two groups were compared.Results:The total effective rate was 95.00%in the observation group,higher than that of 77.50%in the control group(P<0.05).After treatment,the scores of negative symptoms,positive symptoms and general psychopathological symptoms as well as the total scores in the two groups were decreased when compared with those before treatment(P<0.05),and the scores of negative symptoms,positive symptoms and general psychopathological symptoms as well as the total score in the observation group were lower than those in the control group(P<0.05).After treatment,the scores of each dimension of MATRICS Consensus Cognitive Battery(MCCB)in the two groups were increased when compared with those before treatment(P<0.05),and the scores of each dimension of MCCB in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of VEGF and GDNF in the two groups were increased when compared with those before treatment(P<0.05),and the EGF levels were decreased(P<0.05);the levels of VEGF and GDNF in the observation group were higher than those in the control group(P<0.05),and the EGF level was lower(P<0.05).The incidence of adverse reactions was 15.00%in the observation group,compared with that of 12.50%in the control group,there was no significant difference(P>0.05).Conclusion:Shugan Jieyu capsules combined with ziprasidone for schizophrenia can improve clinical effects and cognitive function of patients,and regulate the levels of VEGF,GDNF and EGF with good safety.